- Dermata announced positive topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial, achieving all co-primary endpoints -
- Dermata entered into a Clinical Trial Collaboration Agreement with Revance Therapeutics to study DMT410 with DAXXIFY® for the treatment of axillary hyperhidrosis -
- Raised $8.8 million in gross proceeds from private placement and warrant inducement financings during the first quarter of 2025 -
Read MoreLock'dIn Beverages, a subsidiary of Labor Smart Inc., proudly announces that its premium hydrogen water is now available in every guest room at the iconic ME by Meliá Dubai, further solidifying the brand's position as a leader in functional hydration.
Read MoreAnnounced at CES 2025, the collaboration will give Defined.ai users access to Getty Images' content, allowing customers to train AI models with premium, vetted datasets that compensate creators.
Read MoreThis collaboration marks a major milestone in Proxymity's mission to transform
shareholder communications benefiting both corporates and investors
Vote Connect Global ensures timely communication with 75% of ballots generated for Citi's clients having a market deadline offset of 1 day or less
Investors receive the market deadline date for 31% of total ballots
Read More